September 23,2025
RED FM News Desk
Shares of Tylenol maker Kenvue surged at Tuesday’s opening, bouncing back from a 7.5% drop the previous day after former U.S. President Donald Trump repeatedly claimed, without scientific evidence, that Tylenol may be linked to vaccines and autism. At a White House news conference, Trump advised pregnant women not to take Tylenol (acetaminophen) and warned against giving it to infants. Kenvue rebounded over 6% in early trading, despite hundreds of past lawsuits—most dismissed—alleging a Tylenol-autism connection.
Kenvue strongly rejected any link, warning that discouraging Tylenol use in pregnancy could lead to unsafe alternatives or untreated fevers. The New Jersey–based company, spun off from Johnson & Johnson in 2023, also makes Band-Aids, Listerine, and other household products. Analysts noted that while Trump’s comments could affect consumer confidence, the absence of new scientific findings likely contributed to the stock rebound.
Separately, the U.S. FDA announced it is updating acetaminophen labels, including Tylenol, to reflect research suggesting potential risks of neurological conditions such as autism and ADHD when used during pregnancy. The agency also issued guidance to physicians nationwide. FDA Commissioner Marty Makary emphasized that while evidence is significant, the choice ultimately rests with parents, and acetaminophen may still be reasonable in certain circumstances.
Recent large-scale studies, including the Nurses’ Health Study II and the Boston Birth Cohort, have increasingly suggested a link between prenatal acetaminophen use and conditions like autism and ADHD, with the highest risk associated with regular use throughout pregnancy.
Loading ...
